Author:
Bosch Montserrat,Danés Immaculada,Ballarín Elena,Marrero Patricia,Vancells Guillem,Ortiz-Zúñiga Ángel,Urquizu-Padilla Maria,Rial-Lorenzo Nuria,Lozano-Torres Jordi,Rodríguez-Luna David,Filippi-Arriaga Francesca,Agustí Antònia
Reference22 articles.
1. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;N Engl J Med,2017
2. Alirocumab and cardiovascular outcomes after acute coronary syndrome;Schwartz;N Engl J Med,2018
3. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice;Visseren;Eur Heart J,2021
4. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study;Ray;Eur Heart J Qual Care Clin Outcomes,2022
5. Agencia Española de Medicamentos y Productos Sanitarios. [Informe de Posicionamiento Terapéutico de Evolocumab (Repatha®) en hipercolesterolemia]. Available from: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT_12-2020-evolocumab-Repatha.pdf [accessed 11.07.23].